Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated